Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinica...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/478 |
| _version_ | 1797876163438182400 |
|---|---|
| author | E. V. Borodavina P. A. Isaev A. Yu. Shurinov P. O. Rumyantsev V. V. Krylov K. M. Petrosyan A. D. Kaprin S. A. Ivanov S. O. Podvyaznikov I. S. Romanov A. M. Mudunov K. Yu. Slashchuk R. S. Zhikhorev M. V. Volkonsky R. M. Chagova I. R. Suslova A. I. Khryapa A. Kh. Lepshokova N. L. Fadeeva A. R. Safarova L. P. Kaleykina E. V. Lymar E. M. Chernyakova O. A. Snezhko A. E. Zinkovskaya F. F. Mufazalov E. S. Kuzmina Yu. V. Druzhinina Sh. I. Musin M. R. Mukhitova A. I. Khasanova S. Z. Safina S. L. Kirienko |
| author_facet | E. V. Borodavina P. A. Isaev A. Yu. Shurinov P. O. Rumyantsev V. V. Krylov K. M. Petrosyan A. D. Kaprin S. A. Ivanov S. O. Podvyaznikov I. S. Romanov A. M. Mudunov K. Yu. Slashchuk R. S. Zhikhorev M. V. Volkonsky R. M. Chagova I. R. Suslova A. I. Khryapa A. Kh. Lepshokova N. L. Fadeeva A. R. Safarova L. P. Kaleykina E. V. Lymar E. M. Chernyakova O. A. Snezhko A. E. Zinkovskaya F. F. Mufazalov E. S. Kuzmina Yu. V. Druzhinina Sh. I. Musin M. R. Mukhitova A. I. Khasanova S. Z. Safina S. L. Kirienko |
| author_sort | E. V. Borodavina |
| collection | DOAJ |
| description | Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation. Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study. Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation. |
| first_indexed | 2024-04-10T01:58:48Z |
| format | Article |
| id | doaj.art-90b3f88358a64191b3df59c14333279c |
| institution | Directory Open Access Journal |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| last_indexed | 2024-04-10T01:58:48Z |
| publishDate | 2020-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj.art-90b3f88358a64191b3df59c14333279c2023-03-13T08:43:21ZrusABV-pressОпухоли головы и шеи2222-14682411-46342020-04-01101657210.17650/2222-1468-2020-10-1-65-72384Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian FederationE. V. Borodavina0P. A. Isaev1A. Yu. Shurinov2P. O. Rumyantsev3V. V. Krylov4K. M. Petrosyan5A. D. Kaprin6S. A. Ivanov7S. O. Podvyaznikov8I. S. Romanov9A. M. Mudunov10K. Yu. Slashchuk11R. S. Zhikhorev12M. V. Volkonsky13R. M. Chagova14I. R. Suslova15A. I. Khryapa16A. Kh. Lepshokova17N. L. Fadeeva18A. R. Safarova19L. P. Kaleykina20E. V. Lymar21E. M. Chernyakova22O. A. Snezhko23A. E. Zinkovskaya24F. F. Mufazalov25E. S. Kuzmina26Yu. V. Druzhinina27Sh. I. Musin28M. R. Mukhitova29A. I. Khasanova30S. Z. Safina31S. L. Kirienko32Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииМедицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава РоссииГБУЗ «Московская городская онкологическая больница № 62 Департамента здравоохранения г. Москвы»ГБУЗ «Московская городская онкологическая больница № 62 Департамента здравоохранения г. Москвы»ГБУЗ «Городская клиническая больница им. С. П. Боткина Департамента здравоохранения г. Москвы»ГБУЗ «Онкологический диспансер № 4 Департамента здравоохранения г. Москвы»ГБУЗ «Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)»ГБУЗ РО «Онкологический диспансер»БУЗ «Республиканский клинический онкологический диспансер им. С. Г. Примушко Минздрава Удмуртской Республики»ГАУЗ «Республиканский клинический онкологический диспансер Минздрава Республики Татарстан»ГБУЗ РМ «Республиканский клинический онкологический диспансер»ГБУЗ «Клинический онкологический диспансер № 1» Минздрава Краснодарского краяГБУЗ РК «Республиканский онкологический диспансер»;ГБУЗ РО «Онкологический диспансер»СПбГБУЗ «Городской клинический онкологический диспансер»ГАУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики БашкортостанРегиональный онкологический центр ГУЗ «Салехардская окружная клиническая больница»МКМЦ «Медицинский город»ГАУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики БашкортостанГАУЗ «Республиканский клинический онкологический диспансер Минздрава Республики Татарстан»ГАУЗ «Республиканский клинический онкологический диспансер Минздрава Республики Татарстан»ГАУЗ «Республиканский клинический онкологический диспансер Минздрава Республики Татарстан»ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииBackground. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinical experience with lenvatinib in patients with RR-DTC in the Russian Federation. Materials and methods. The data from 18 clinical sites in Russia was analyzed for the period December 2015 and September 2019. Seventyseven patients with histologically verified DTC, proven resistance to radioactive iodine therapy, and tumor progression (according to the Response Evaluation Criteria In Solid Tumors 1.1 criteria) were included in the study. Results.Median progression-free survival in patients included into analysis (n = 72) was 26.1 months. In patients who responded to therapy (including those with partial and complete response), median progression-free survival reached 36.2 months, which is higher than that reported in the updated results of the SELECT study (33.1 months). Lenvatinib-associated adverse events (AEs) were observed in 87 % of patients. Severe AEs were registered in 18.2 % of participants. In 6.5 % of cases, AEs lead to lenvatinib cessation; in 74 % of cases, AEs required dose reduction.Conclusion. Our findings suggest high efficacy and good tolerability of lenvatinib in patients with RR-DTC in routine clinical practice in the Russian Federation.https://ogsh.abvpress.ru/jour/article/view/478ленватиниб, радиойодрезистентный рак щитовидной железы, клиническая практика, выживаемость без прогрессирования |
| spellingShingle | E. V. Borodavina P. A. Isaev A. Yu. Shurinov P. O. Rumyantsev V. V. Krylov K. M. Petrosyan A. D. Kaprin S. A. Ivanov S. O. Podvyaznikov I. S. Romanov A. M. Mudunov K. Yu. Slashchuk R. S. Zhikhorev M. V. Volkonsky R. M. Chagova I. R. Suslova A. I. Khryapa A. Kh. Lepshokova N. L. Fadeeva A. R. Safarova L. P. Kaleykina E. V. Lymar E. M. Chernyakova O. A. Snezhko A. E. Zinkovskaya F. F. Mufazalov E. S. Kuzmina Yu. V. Druzhinina Sh. I. Musin M. R. Mukhitova A. I. Khasanova S. Z. Safina S. L. Kirienko Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation Опухоли головы и шеи ленватиниб, радиойодрезистентный рак щитовидной железы, клиническая практика, выживаемость без прогрессирования |
| title | Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation |
| title_full | Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation |
| title_fullStr | Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation |
| title_full_unstemmed | Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation |
| title_short | Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation |
| title_sort | efficacy and tolerability of lenvatinib in patients with radioiodine refractory differentiated thyroid cancer results of a multicenter observational study in the russian federation |
| topic | ленватиниб, радиойодрезистентный рак щитовидной железы, клиническая практика, выживаемость без прогрессирования |
| url | https://ogsh.abvpress.ru/jour/article/view/478 |
| work_keys_str_mv | AT evborodavina efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT paisaev efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT ayushurinov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT porumyantsev efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT vvkrylov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT kmpetrosyan efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT adkaprin efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT saivanov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT sopodvyaznikov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT isromanov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT ammudunov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT kyuslashchuk efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT rszhikhorev efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT mvvolkonsky efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT rmchagova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT irsuslova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT aikhryapa efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT akhlepshokova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT nlfadeeva efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT arsafarova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT lpkaleykina efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT evlymar efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT emchernyakova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT oasnezhko efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT aezinkovskaya efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT ffmufazalov efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT eskuzmina efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT yuvdruzhinina efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT shimusin efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT mrmukhitova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT aikhasanova efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT szsafina efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation AT slkirienko efficacyandtolerabilityoflenvatinibinpatientswithradioiodinerefractorydifferentiatedthyroidcancerresultsofamulticenterobservationalstudyintherussianfederation |